Skip to content

Study · Non-randomized trial · n = 30 · 2003

4 results

[Effect of thymosin alpha 1 on cellular immune function in elderly patients with malignant tumor].

Yang YM, Lu XY, Huang WD, Shen MY

Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences1 Aug 2003Cited by 1 (Europe PMC)

PMID12970939 (opens in a new tab)DOI10.3785/j.issn.1008-9292.2003.04.017 (opens in a new tab)PepBankPUB-12970939
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In elderly patients with malignant tumor, thymosin alpha‑1 increased the number of CD4 cells.

    In plain wordsIn older people with cancer, thymosin alpha‑1 raised the number of CD4 immune cells compared with before treatment.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseCD4 cell number
    Study

    n = 30

    Comparator
    Before treatment
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    1.6 mg q.d. for the first month, then q.o.d. for the following month · subcutaneous · 2 monthsAs given in this study (human).

    Source sentences

    Summary
    Treatment of thymosin alpha 1 increased the number of CD4 cells
    2 context sentences
    Summary · context
    Thirty patients with malignant tumor were injected with thymosin alpha 1 subcutaneously at the dose of 1.6 mg q.d. for the first month and q.o.d. for the following month.
    Summary · context
    The number of T cell subgroups and the activity of NK cell in peripheral blood were detected and the quality of life of the patients were evaluated before treatment and at the end of treatment.
  2. 02HumanNon-randomized trialEfficacy outcome

    In elderly patients with malignant tumor, thymosin alpha‑1 improved NK cell activity.

    In plain wordsIn older people with cancer, thymosin alpha‑1 raised natural killer cell activity compared with before treatment.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseNK cell activity
    Study

    n = 30

    Comparator
    Before treatment
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    1.6 mg q.d. for the first month, then q.o.d. for the following month · subcutaneous · 2 monthsAs given in this study (human).

    Source sentences

    Summary
    Treatment of thymosin alpha 1 increased the number of CD4 cells and improved the NK activity, and also improved the quality of life of the elderly patients with malignant tumor.
    2 context sentences
    Summary · context
    Thirty patients with malignant tumor were injected with thymosin alpha 1 subcutaneously at the dose of 1.6 mg q.d. for the first month and q.o.d. for the following month.
    Summary · context
    The number of T cell subgroups and the activity of NK cell in peripheral blood were detected and the quality of life of the patients were evaluated before treatment and at the end of treatment.
  3. 03HumanNon-randomized trialEfficacy outcome

    In elderly patients with malignant tumor, thymosin alpha‑1 improved quality of life.

    In plain wordsIn older people with cancer, quality of life was better after thymosin alpha‑1 than before treatment.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseQuality of life
    Study

    n = 30

    Comparator
    Before treatment
    Outcome group
    Quality of life · Whole body
    Studied dose
    1.6 mg q.d. for the first month, then q.o.d. for the following month · subcutaneous · 2 monthsAs given in this study (human).

    Source sentences

    Summary
    and also improved the quality of life of the elderly patients with malignant tumor.
    2 context sentences
    Summary · context
    Thirty patients with malignant tumor were injected with thymosin alpha 1 subcutaneously at the dose of 1.6 mg q.d. for the first month and q.o.d. for the following month.
    Summary · context
    The number of T cell subgroups and the activity of NK cell in peripheral blood were detected and the quality of life of the patients were evaluated before treatment and at the end of treatment.
  4. 04HumanNon-randomized trialSafety outcome

    In elderly patients with malignant tumor, no side effects were found with thymosin alpha‑1.

    In plain wordsIn older people with cancer, no side effects were found with thymosin alpha‑1.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeSide effects
    Study

    n = 30

    Comparator
    Before treatment
    Outcome group
    Adverse events · Whole body
    Studied dose
    1.6 mg q.d. for the first month, then q.o.d. for the following month · subcutaneous · 2 monthsAs given in this study (human).

    Source sentences

    Summary
    There were no side effects found.
    2 context sentences
    Summary · context
    Thirty patients with malignant tumor were injected with thymosin alpha 1 subcutaneously at the dose of 1.6 mg q.d. for the first month and q.o.d. for the following month.
    Summary · context
    The number of T cell subgroups and the activity of NK cell in peripheral blood were detected and the quality of life of the patients were evaluated before treatment and at the end of treatment.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    12 Oct 2026, 17:28 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.